This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Jul 11;381(2):192-193.

doi: 10.1056/NEJMc1906058.

Andexanet Alfa for Bleeding with Factor Xa Inhibitors. Reply

Truman J Milling Jr¹, Stuart J Connolly², Pamela B Conley³

Affiliations

Affiliations

¹ Seton Dell Medical School Stroke Institute, Austin, TX.
² Population Health Research Institute, Hamilton, ON, Canada connostu@phri.ca.
³ Portola Pharmaceuticals, South San Francisco, CA.

PMID: 31291534
DOI: 10.1056/NEJMc1906058

Comment

Andexanet Alfa for Bleeding with Factor Xa Inhibitors. Reply

Truman J Milling Jr et al. N Engl J Med. 2019.

. 2019 Jul 11;381(2):192-193.

doi: 10.1056/NEJMc1906058.

Authors

Truman J Milling Jr¹, Stuart J Connolly², Pamela B Conley³

Affiliations

¹ Seton Dell Medical School Stroke Institute, Austin, TX.
² Population Health Research Institute, Hamilton, ON, Canada connostu@phri.ca.
³ Portola Pharmaceuticals, South San Francisco, CA.

PMID: 31291534
DOI: 10.1056/NEJMc1906058

No abstract available

PubMed Disclaimer

Comment on

Andexanet Alfa for Bleeding with Factor Xa Inhibitors.
Tomoda H. Tomoda H. N Engl J Med. 2019 Jul 11;381(2):191. doi: 10.1056/NEJMc1906058. N Engl J Med. 2019. PMID: 31291532 No abstract available.
Andexanet Alfa for Bleeding with Factor Xa Inhibitors.
Ponnusamy V, Sinha A, Kupfer Y. Ponnusamy V, et al. N Engl J Med. 2019 Jul 11;381(2):191-192. doi: 10.1056/NEJMc1906058. N Engl J Med. 2019. PMID: 31291533 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.